Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Argye Hillis MD, MA
Argye Elizabeth Hillis MD, MA Associate Editor
Marinos Dalakas MD
Marinos C. Dalakas MD Advisory Board
Nina Schor MD, PhD
Nina F. Schor MD, PhD Advisory Board
See All Experts
Published in Neurology

Journal Scan / Research · May 12, 2024

Serum SV2A as a Biomarker for Early Diagnosis of Alzheimer's Disease

Alzheimer's Research &Therapy

 

 Save  Recommend
 Share

Additional Info

Alzheimer's Research &Therapy
Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease
Alzheimers Res Ther 2024 Apr 13;16(1)82, X Wang, X Zhang, J Liu, J Zhang, C Liu, Y Cui, Q Song, Y Hou, Y Wang, Q Zhang, Y Zhang, Y Fan, J Jia, P Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated